<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BIORXIV</journal-id>
<journal-title-group>
<journal-title>bioRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/451948</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="author-type">
<subject>Regular Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>New Results</subject>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Biochemistry</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>SPR-measuredkinetics of PROTAC ternary complexes influence target degradation rate</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0198-9108</contrib-id>
<name>
<surname>Roy</surname>
<given-names>Michael J.</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Winkler</surname>
<given-names>Sandra</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hughes</surname>
<given-names>Scott J.</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Whitworth</surname>
<given-names>Claire</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Galant</surname>
<given-names>Michael</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Farnaby</surname>
<given-names>William</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rumpel</surname>
<given-names>Klaus</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8654-1670</contrib-id>
<name>
<surname>Ciulli</surname>
<given-names>Alessio</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, James Black Centre</institution>, Dow Street, Dundee, DD1 5EH, <country>United Kingdom</country>.</aff>
<aff id="a2"><label>2</label><institution>Boehringer Ingelheim RCV GmbH &#x0026; Co KG</institution>, 1221 Vienna, <country>Austria</country>.</aff>
</contrib-group>
<pub-date pub-type="epub"><year>2018</year></pub-date>
<elocation-id>451948</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>10</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>24</day>
<month>10</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>10</month>
<year>2018</year>
</date>
</history><permissions><copyright-statement>&#x00A9; 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2018</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="451948.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>ABSTRACT</title>
<p>Bifunctional degrader molecules, known as proteolysis-targeting chimeras (PROTACs), function by recruiting a target to an E3 ligase, via a target:PROTAC:ligase ternary complex. Despite the importance of this key intermediate species, no method to monitor ternary complex kinetics has been reported, and it remains to be addressed how this might impact on the kinetics of protein degradation. Here, we develop an SPR-based assay to quantify the stability of PROTAC-induced ternary complexes by measuring for the first time the kinetics of their formation and dissociation. We benchmark our assay using four PROTACs that target the bromodomains (BDs) of BET proteins Brd2, Brd3 and Brd4 to the E3 ligase VHL. We reveal marked differences in ternary complex off-rates for different PROTACs that form either cooperative or non-cooperative complexes. The positively cooperative degrader MZ1 forms comparatively stable and long-lived ternary complexes with eitherBrd4<sup>BD2</sup> or Brd2<sup>BD2</sup> and VHL. Equivalent complexes with Brd3<sup>BD2</sup> are destabilized due toa single amino acid difference (Glu/Gly swap) present in the bromodomain. We observe that this difference in ternary complex dissociative half-life correlates to a greater initial rate of intracellular degradation of Brd2 and Brd4 relative to Brd3. These findings establish a novel assay to measure the kinetics of PROTAC ternary complexes and elucidate the important kinetic parameters that drive effective target degradation.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>PROTACs</kwd>
<kwd>ternary complexes</kwd>
<kwd>surface plasmon resonance</kwd>
<kwd>kinetics</kwd>
<kwd>protein-protein interactions</kwd>
<kwd>cooperativity</kwd>
</kwd-group>
<counts>
<page-count count="9"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<p>PROTACs are bivalent molecules consisting of ligands for each of a target protein and an E3 ligase, joined <italic>via</italic> a linker.<sup><xref ref-type="bibr" rid="c1">1</xref>&#x2013;<xref ref-type="bibr" rid="c2">2</xref></sup> PROTAC behaviour can be modelled by three-body binding equilibria.<sup><xref ref-type="bibr" rid="c3">3</xref></sup> Formation of a tar-get:PROTAC:ligase ternary complex triggers proximity-dependent target protein ubiquitylation and degradation <italic>via</italic> the ubiquitin-proteasome-system.<sup><xref ref-type="bibr" rid="c2">2</xref>,<xref ref-type="bibr" rid="c4">4</xref></sup> PROTAC drug discovery is rapidly advancing in both academia and industry, fuelled by both improvement in drug-like properties and broader recognition of mechanistic advantages of degradation over inhbition.<sup><xref ref-type="bibr" rid="c1">1</xref>, <xref ref-type="bibr" rid="c5">5</xref>&#x2013;<xref ref-type="bibr" rid="c6">6</xref></sup> PROTACs offer potential for improved selectivity beyond that of the constituent target ligand, by harnessing additional stabilising or destabilising <italic>de novo</italic> protein-protein or protein-linker interactions formed <italic>via</italic> the ternary complex.<sup><xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c7">7</xref>&#x2013;<xref ref-type="bibr" rid="c9">9</xref></sup> Developing new tools to understand cooperativity/avidity effects in PROTAC design is thus of significant interest. Although functional degraders can be generated in the absence of positive cooperativity,<sup><xref ref-type="bibr" rid="c8">8</xref>, <xref ref-type="bibr" rid="c10">10</xref></sup> mounting evidence suggests enhancing cooperativity could be an effective strategy in PROTAC design. Cooperativity is expected to counter the &#x2018;hook effect&#x2019; exhibited by bifunctional molecules, <sup><xref ref-type="bibr" rid="c3">3</xref></sup> thereby widening the concentration window for PROTAC activity, and could enable use of weaker-affinity ligands.<sup><xref ref-type="bibr" rid="c11">11</xref>&#x2013;<xref ref-type="bibr" rid="c12">12</xref></sup> Despite a growing literature of methods to measure thermodynamics of PROTACs at steady-state,<sup><xref ref-type="bibr" rid="c1">1</xref>&#x2013;<xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c8">8</xref>&#x2013;<xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c13">13</xref>&#x2013;<xref ref-type="bibr" rid="c14">14</xref></sup> there is currently a dearth of methods to measure kinetics of formation and dissociation of PROTAC ternary complexes in real-time.We were thus interested in exploring surface plasmon resonance (SPR) as a suitable label-free technique to monitor the kinetics of PROTAC-induced ternary complexes, the required intermediate species in the mechanism. <sup><xref ref-type="bibr" rid="c4">4</xref></sup> Herein we develop the first SPR-based assay to quantitatively measure the kinetics ofcomplex formation and dissociation, which we use to characterise the lifetime of ternary complexes composed of bromodomain-containing target proteins, PROTACs, and the von Hippel-Lindau E3 ligase (VHL).</p>
<p>SPR has previously been utilised to characterise three-body binding systems(including complexes composed of protein, DNA and small-molecules),<sup><xref ref-type="bibr" rid="c15">15</xref>&#x2013;<xref ref-type="bibr" rid="c18">18</xref></sup> which can be experimentally involving due to the complex nature of the binding equilibria.<sup><xref ref-type="bibr" rid="c3">3</xref></sup> We sought a general-purpose and conceptually-simple assay format to study PROTACs ternary complexes. Importantly, we recognised for bivalent molecules that the &#x2018;hook effect&#x2019; would preclude use of saturating concentrations of PROTAC in the running buffer. We reasoned that by immobilising the E3 ligase, a single sensor surface might be utilised to measure diverse PROTAC/target combinations. To improve uniform presentation on the chip surface, we designed a VHL:ElonginB:ElonginC (VCB) construct harboring an AviTag sequence C-terminal to ElonginB for site-specific biotinylation (hereafter &#x2018;biotin-VHL&#x2019;).<sup><xref ref-type="bibr" rid="c19">19</xref>&#x2013;<xref ref-type="bibr" rid="c20">20</xref></sup></p>
<p>Using a Biacore T200 SPR instrument and streptavidin-immobilised biotin-VHL, we measured the kinetics and affinity ofVHL binding for a concentration series of either PROTAC alone(to form binary complex with VHL, <italic>K</italic><sub>D</sub><sup>binary</sup>) or PROTAC pre-incubated with saturating concentrations of target protein (to form ternary complex with VHL, <italic>K</italic><sub>D</sub><sup>ternary</sup>) (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Experiments were performed in either multi-cycle (binary) or single-cycle (ternary) format without regeneration, to ensure a maximally stable surface and reduce experimental run-times for PROTAC:BD complexes exhibiting slow dissociation kinetics.<sup><xref ref-type="bibr" rid="c21">21</xref></sup> Doubly-referenced replicate data were fitted globally (over multiple surface densities where applicable) to a 1:1 Langmuir binding modelincorporating a parameter for mass transfer effects, to determine kinetic constants (<italic>k<sub>on</sub></italic>, <italic>k<sub>off</sub></italic>) from which dissociation constants were calculated (<italic>K</italic><sub>D</sub> = <italic>k</italic><sub>off</sub> / <italic>k</italic><sub>on</sub>). Cooperativity (&#x03B1;) was calculated as the ratio <italic>K</italic><sub>D</sub><sup>binary</sup>/<italic>K</italic><sub>D</sub><sup>ternary</sup>.</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><p>Schematic of SPR approach (A-B) and representative binding data (C).</p></caption>
<graphic xlink:href="451948_fig1.tif"/>
</fig>
<p>To benchmark the assay, we utilised the PROTAC MZ1, which forms a highly cooperative ternary complex with VHL and Brd4<sup>BD2</sup> that we have previously characterised both biophysically and structurally.<sup><xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c7">7</xref>, <xref ref-type="bibr" rid="c10">10</xref></sup> In addition to MZ1, we selected three other PROTACs with ITC-measured affinities for ternary complex formation with VHL/BET bro-modomains (<xref ref-type="fig" rid="fig5">Chart 1</xref>).<sup><xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c10">10</xref></sup> Combined, these encompass a range of both binary binding affinities and ternary complex cooperativities (both positive and negative). This set includes MZ1 and AT1, two positively-cooperative PROTACs based on a triazolodiazepine BET inhibitor JQ1 (Ligand A, <xref ref-type="fig" rid="fig5">Chart 1</xref>), as well as MZP55 and MZP61, two negatively-cooperative PROTACs based on a more potent tetrahydroisoquinolone BET inhibitor I-BET726 (ligand B, <xref ref-type="fig" rid="fig5">Chart 1</xref>).</p>
<fig id="fig5" position="float" fig-type="figure">
<label>Chart 1.</label>
<caption><p>PROTACs utilised in this study.</p></caption>
<graphic xlink:href="451948_fig5.tif"/>
</fig>
<p>SPR binding studies were performed with MZ1, AT1, MZP55 and MZP61 alone (binary) or in complex with Brd4<sup>BD2</sup> as a representative BET bromodomain (ternary), and binding data compared to the ITC-obtained values (<xref ref-type="table" rid="tbl1">Table 1</xref>, Supplementary Table S1, Figure S1).<sup><xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c10">10</xref></sup> For the panel of PROTACs evaluated, the measured <italic>K</italic><sub>D</sub> values for binary and ternary complexes, as well as the calculated values for the both cooperativity andchange in complex stability (&#x2206;&#x2206;G), were remarkably comparable using either ITC or SPR (<xref ref-type="table" rid="tbl1">Table 1</xref>). For MZP61and MZP55 some nonspecific effects were observed for binary binding to VHL (Supplementary Figure S1); in the case of MZP61 these effects were sufficiently pronounced as to preclude accurate kinetic fitting, so steady state fitting wasused to measure <italic>K</italic><sub>D</sub><sup>binary</sup>.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1:</label>
<caption>
<title>Binding of PROTACs or PROTAC:Brd4BD2 complexes to immobilized VHL (SPR) and comparison to ITC data.</title></caption>
<graphic xlink:href="451948_tbl1.tif"/>
</table-wrap>
<p>Relative to the binary equilibria, the VHL:MZ1:Brd4<sup>BD2</sup> ternary complex displayed both a faster <italic>k<sub>on</sub></italic> and slower <italic>k</italic><sub>off</sub>,leading to the tighter <italic>K</italic><sub>D</sub><sup>ternary</sup> and significant positive cooperativity (&#x03B1; &#x2248; 20) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="table" rid="tbl1">Table 1</xref>, Supplementary Table S1). As anticipated, the VHL:AT1:Brd4 <sup>BD2</sup> ternary complex also exhibited positive cooperativity (&#x03B1;&#x2248; 5). In stark contrast, ternary complexes formed by either of MZP55 and MZP61 with Brd4<sup>BD2</sup> had very fast dissociation kinetics(>80-fold faster than the VHL:MZ1:Brd4<sup>BD2</sup> complex) reflecting overall negative cooperativity, with the most negatively-cooperative ternary complex being formed by MZP61 (Supplementary Table S1, Figure S1). Whilst we have shown that both the ITC and SPR approaches are complimentary and yield similar values, the notable advantages of our SPR method are increased throughput and yielding kinetic information, including estimates of the lifetime of the ternary complex. This information is invaluable to better understand PROTAC function and ternary complex stability in an enzymatic context,<sup><xref ref-type="bibr" rid="c4">4</xref></sup> analogously to how quantification of inhibitor residence time has helped to understand pharmacological function in certain occupancy-driven small-molecule contexts.<sup><xref ref-type="bibr" rid="c22">22</xref></sup></p>
<p>MZ1 has been shown to degrade Brd4 more potently than Brd2 or Brd3 (despite near equipotent binding of the constituent warhead ligand to all BET bromodomains),<sup><xref ref-type="bibr" rid="c7">7</xref>, <xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c23">23</xref></sup> resulting from the high thermodynamic stability of the VCB:MZ1:Brd4<sup>BD2</sup> complex.<sup><xref ref-type="bibr" rid="c2">2</xref></sup> We sought to quantify the overall kinetics of VHL:PROTAC:BD ternary complexes for the different BET bromodomains (<xref ref-type="fig" rid="fig2">Figure 2</xref>, Supplementary Table S2, Figures S2, S3). Ternary complexes consisting of VHL, MZ1 and the first bromodomain (BD1) of either Brd2, Brd3, or Brd4 all displayed very fast dissociation kinetics (t<sub>1/2</sub> &#x003C; 1 sec), resulting overall in either low positive cooperativity or no cooperativity (&#x03B1; &#x2248; 1). In the case of the second bromodomains (BD2), we were struck by the significantly longer ternary half-life of the VCB:MZ1:BD ternary complexes with Brd2<sup>BD2</sup> and Brd4<sup>BD2</sup> (t<sub>1/2</sub> &#x2248; 70 and 130 sec respectively) relative to the more short-lived ternary complex with Brd3<sup>BD2</sup> (t<sub>1/2</sub> &#x2248; 6 sec).</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2.</label>
<caption><p>SPR sensorgrams for MZ1:BD complexes binding to immobilized VHL.</p></caption>
<graphic xlink:href="451948_fig2.tif"/>
</fig>
<p>Overlay of crystal structures of either Brd2<sup>BD2</sup> (PDB: 3ONI) or Brd3<sup>BD2</sup> (PDB: 3S92) in complex with JQ1 and the VCB:MZ1:Brd4<sup>BD2</sup> structure (PDB: 5T35),<sup><xref ref-type="bibr" rid="c2">2</xref></sup> suggested that ternary complex formation could be influenced by a single amino acid residue difference (Glu<sup>344</sup> within the ZA loop of Brd3<sup>BD2</sup>, which corresponds to Gly<sup>382</sup> and Gly<sup>286</sup> in Brd2<sup>BD2</sup> and Brd4<sup>BD2</sup>) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). In an equivalent VCB:MZ1:Brd3<sup>BD2</sup> complex, the side-chain of Glu<sup>344</sup> would induce severe steric clash with the VHL:MZ1 portion of the complex, leading to destabilisation. We therefore generated reciprocal point mutant swaps and measured ternary complex formation by SPR with MZ1 or AT1. In all cases, the resulting SPR binding profiles reflected the effect predicted for the point mutation. The G-to-E point mutation in Brd4<sup>BD2</sup> or Brd2<sup>BD2</sup> shortened the ternary complex half-life, decreasing cooperativity and complex stability; whilst the reverse point mutation in Brd3<sup>BD2</sup> extended the ternary half-life to resemble the profile for Brd4<sup>BD2</sup> and correspondingly increased cooperativity and stability (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, Supplementary Table S2, Figure S4). As a cross-validation, we evaluated these complexes in a competitive fluorescence polarization (FP) assay; measuring VHL binding of PROTAC or a PROTAC:BD binary complex, <italic>via</italic> displacement of a fluorescent HIF-1&#x03B1; peptide probe (Supplementary Table S2, Figure S5). Good correlation was observed between SPR-fitted dissociation constants (<italic>K</italic><sub>D</sub>) and FP-derived inhibition constants (<italic>K</italic><sub>I</sub>) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Cooperativity values were also comparable using either approach (Supplementary Table S2). Together, these results underscore the robustness of our SPR approach, and further support the conclusion that the described VCB:MZ1:Brd4<sup>BD2</sup> structure (PDB: 5T35)<sup><xref ref-type="bibr" rid="c2">2</xref></sup> reflects the predominant (long-lived) species present in solution.</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3.</label>
<caption><p>A. Overlay of Brd2<sup>BD2</sup> (PDB: 3ONI) and Brd3<sup>BD2</sup> (PDB: 3S92) with the crystal structure of the VCB:MZ1:Brd4<sup>BD2</sup> ternary complex (PDB: 5T35) suggests the VHL:MZ1:Brd3<sup>BD2</sup> ternary complex could be destabilized by steric clash with VHL:MZ1 of a single amino acid within the ZA loop. B. Reciprocal exchange of this single Gly/Glu residue in Brd4<sup>BD2</sup> (i,iii) or Brd3<sup>BD2</sup> (ii, iv) yields a corresponding swap of the kinetic profile in the resulting VHL:MZ1:BD ternary complex SPR sensorgram.</p></caption>
<graphic xlink:href="451948_fig3.tif"/>
</fig>
<fig id="fig4" position="float" fig-type="figure">
<label>Figure 4.</label>
<caption><p>A. Correlation between binary (MZ1) and ternary (MZ1:BD complex) binding to VHL <italic>via</italic> SPR or FP (mean &#x00B1; SD). B. Initial degradation profile for BET proteins in HEK293 cells in response to MZ1 treatment (333 nM), with initial degradation rates (&#x019B;) estimated from data fitting (mean &#x00B1; SEM, N = 3) and SPR ternary half-livesfor corresponding VHL:MZ1:BD2 complexes (mean &#x00B1; SD for N=2).</p></caption>
<graphic xlink:href="451948_fig4.tif"/>
</fig>
<p>These SPR data illustrate kinetically a mechanistic difference between different PROTAC &#x2018;architypes&#x2019;.<sup><xref ref-type="bibr" rid="c10">10</xref></sup> On the one hand, MZP55 and MZP61 are PROTACs with high binary target affinity (for Brd4), but low or negative cooperativity, thus likely forming highly-populated binary complexes but a very transient ternary complex. In contrast, MZ1 and AT1 exhibit weaker binary target affinity (for Brd4), but this is compensated for in the case of Brd4<sup>BD</sup> by significant positive cooperativity (to form stable ternary complexes). This latter case is predicted to fit a &#x2018;rapid equilibrium&#x2019; kinetics model, where a rate-limiting ubiquitination step is dependent on the concentration of PROTAC-induced ternary com-plex.<sup><xref ref-type="bibr" rid="c4">4</xref></sup> In this regime, an extension in ternary complex stability, and hencelifetime, would be expected to increase rates of target protein ubiquitination and degradation, particularly at early time points prior to countervailing factors such as protein resynthesis or feedback mechanisms.</p>
<p>We wished to examine this possibility in a cellular context, in light of the greater stability of ternary complexes of MZ1 with Brd2<sup>BD2</sup> or Brd4<sup>BD2</sup> and VHL, relative to the equivalent complex with Brd3<sup>BD2</sup>. Time-course studies were performed to measure initial rate of degradation of Brd4, Brd3, or Brd2 in response to treatment of HEK293 cells with MZ1 (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). We observed rapid degradation of Brd2 and both isoforms of Brd4, whilst degradation of Brd3 was significantly slower (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, Supplementary Table S3). Recent results by an independent group, published whilst this manuscript was under preparation, strongly support our conclusion.<sup><xref ref-type="bibr" rid="c23">23</xref></sup> Consistent with our data, Riching <italic>et. al.</italic> observed more rapid initial rates of ubiquitination and degradation of Brd2 and Brd4 than Brd3 in response to MZ1 treatment.<sup><xref ref-type="bibr" rid="c23">23</xref></sup> Together, these observations strongly suggest a mechanistic link between the relative half-life of a given target-PROTAC-E3 ligase ternary complex and initial rates of target degradation, which drives a faster and more profound target depletion in cells.</p>
<p>In conclusion, we demonstrate a simple and robust SPR-based method to quantify for the first time the stability of target-PROTAC-ligase ternary complexes by measuring the kinetics of their formation and dissociation. We demonstrate that our surface-based SPR method yields values for affinity, cooperativity (&#x03B1;) and complex stability comparable to ITC in solution,<sup><xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c10">10</xref></sup> with increased throughput and yielding additional kinetic information not achievable using other assays described to date. We show by SPR that a single residue can impart significant changes in cooperativity, stability and dissociative half-lives of ternary complexes formed with different but highly conserved target proteins. Lastly, we observe that these kinetic differences of ternary complexes correlate to relative initial rates of target degradation. Together, these findings establish a new assay for PROTAC ternary complex kinetics and illuminate on ternary complex stability and dissociative half-lives as key optimization parameters for PROTAC design and discovery campaigns. We anticipate that our SPR kinetic assay will become an established tool to drive PROTAC development and to further elucidate dynamic processes governing their mode of action. Beyond PROTACs, this assay could be applied more broadly to study three-body binding equilibria induced by other classes of heterobivalent molecules.<sup><xref ref-type="bibr" rid="c24">24</xref></sup></p>
</sec>
<sec id="s2">
<title>ASSOCIATED CONTENT</title>
<sec id="s2a">
<title>Supporting Information</title>
<p>Supplementary results (Tables S1-S3 and Figures S1-S5); supplementary materials and methods sections; supplementary references.</p>
</sec>
</sec>
<sec id="s3">
<title>AUTHOR INFORMATION</title>
<sec id="s3a">
<title>Corresponding Author</title>
<p>Corresponding Author: Email: &#x002A; <email>a.ciulli@dundee.ac.uk</email></p>
<p>Homepage: <ext-link ext-link-type="uri" xlink:href="http://www.lifesci.dundee.ac.uk/groups/alessio-ciulli/">http://www.lifesci.dundee.ac.uk/groups/alessio-ciulli/</ext-link></p>
<p>ORCID IDs:</p>
<p>Michael Roy: 0000-0003-0198-9108</p>
<p>William Farnaby: 0000-0001-8610-932X</p>
<p>Alessio Ciulli: 0000-0002-8654-1670</p>
</sec>
</sec>
<sec id="s4" sec-type="funding">
<title>Funding Sources</title>
<p>This project has received funding from the European Research Council (ERC) under the European Union&#x2019;s Seventh Framework Programme (FP7/2007-2013) as a Starting Grant to A.C. (grant agreement no. ERC-2012-StG-311460 DrugE3CRLs),and by Boehringer Ingelheim. Biophysics and drug discovery activities at Dundee were supported by Wellcome Trust strategic awards (100476/Z/12/Z and 094090/Z/10/Z, respectively) to the Division of Biological Chemistry and Drug Discovery.</p>
</sec>
<sec id="s5">
<title>Notes</title>
<p>The A.C. laboratory receives sponsored research support from Boehringer Ingelheim and Nurix, Inc. A.C. is a scientific founder, director and shareholder of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms.</p>
</sec>
</body>
<back>
<ack>
<title>ACKNOWLEDGMENT</title>
<p>We thank chemists of the Ciulli group and at B.I. for the gifts of compounds; K. H. Chan for discussions; G. Glendinning and S. Mayer for compound logistics; the Dundee MRC PPU Reagents and Services facility (mrcppureagents.dundee.ac.uk)
for the gift of the GST-BirA construct and for DNA sequencing services; and the Dundee Fingerprints Proteomics Facility
(proteomics.lifesci.dundee.ac.uk) for ESI-MS of protein samples.</p>
</ack>
<ref-list>
<title>REFERENCES</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Bondeson</surname>, <given-names>D. P.</given-names></string-name>; <string-name><surname>Crews</surname>, <given-names>C. M.</given-names></string-name>, <article-title>Targeted Protein Degradation by Small Molecules</article-title>. <source>Annu Rev Pharmacol Toxicol</source> <year>2017</year>, <volume>57</volume>, <fpage>107</fpage>&#x2013;<lpage>123</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Gadd</surname>, <given-names>M. S.</given-names></string-name>; <string-name><surname>Testa</surname>, <given-names>A.</given-names></string-name>; <string-name><surname>Lucas</surname>, <given-names>X.</given-names></string-name>; <string-name><surname>Chan</surname>, <given-names>K. H.</given-names></string-name>; <string-name><surname>Chen</surname>, <given-names>W.</given-names></string-name>; <string-name><surname>Lamont</surname>, <given-names>D. J.</given-names></string-name>; <string-name><surname>Zengerle</surname>, <given-names>M.</given-names></string-name>; <string-name><surname>Ciulli</surname>, <given-names>A.</given-names></string-name>, <article-title>Structural basis of PROTAC cooperative recognition for selective protein degradation</article-title>. <source>Nat Chem Biol</source> <year>2017</year>, <volume>13</volume> (<issue>5</issue>), <fpage>514</fpage>&#x2013;<lpage>521</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Douglass</surname>, <given-names>E. F.</given-names>, <suffix>Jr.</suffix></string-name>; <string-name><surname>Miller</surname>, <given-names>C. J.</given-names></string-name>; <string-name><surname>Sparer</surname>, <given-names>G.</given-names></string-name>; <string-name><surname>Shapiro</surname>, <given-names>H.</given-names></string-name>; <string-name><surname>Spiegel</surname>, <given-names>D. A.</given-names></string-name>, <article-title>A comprehensive mathematical model for three-body binding equilibria</article-title>. <source>J Am Chem Soc</source> <year>2013</year>, <volume>135</volume> (<issue>16</issue>), <fpage>6092</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Fisher</surname>, <given-names>S. L.</given-names></string-name>; <string-name><surname>Phillips</surname>, <given-names>A. J.</given-names></string-name>, <article-title>Targeted protein degradation and the enzymology of degraders</article-title>. <source>Curr Opin Chem Biol</source> <year>2018</year>, <volume>44</volume>, <fpage>47</fpage>&#x2013;<lpage>55</lpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Churcher</surname>, <given-names>I.</given-names></string-name>, <article-title>Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?</article-title> <source>J Med Chem</source> <year>2018</year>, <volume>61</volume> (<issue>2</issue>), <fpage>444</fpage>&#x2013;<lpage>452</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Burslem</surname>, <given-names>G. M.</given-names></string-name>; <string-name><surname>Smith</surname>, <given-names>B. E.</given-names></string-name>; <string-name><surname>Lai</surname>, <given-names>A. C.</given-names></string-name>; <string-name><surname>Jaime-Figueroa</surname>, <given-names>S.</given-names></string-name>; <string-name><surname>McQuaid</surname>, <given-names>D. C.</given-names></string-name>; <string-name><surname>Bondeson</surname>, <given-names>D. P.</given-names></string-name>; <string-name><surname>Toure</surname>, <given-names>M.</given-names></string-name>; <string-name><surname>Dong</surname>, <given-names>H.</given-names></string-name>; <string-name><surname>Qian</surname>, <given-names>Y.</given-names></string-name>; <string-name><surname>Wang</surname>, <given-names>J.</given-names></string-name>; <string-name><surname>Crew</surname>, <given-names>A. P.</given-names></string-name>; <string-name><surname>Hines</surname>, <given-names>J.</given-names></string-name>; <string-name><surname>Crews</surname>, <given-names>C. M.</given-names></string-name>, <article-title>The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study</article-title>. <source>Cell Chem Biol</source> <year>2018</year>, <volume>25</volume> (<issue>1</issue>), <fpage>67</fpage>&#x2013;<lpage>77 e3</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Zengerle</surname>, <given-names>M.</given-names></string-name>; <string-name><surname>Chan</surname>, <given-names>K. H.</given-names></string-name>; <string-name><surname>Ciulli</surname>, <given-names>A.</given-names></string-name>, <article-title>Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4</article-title>. <source>ACS Chem Biol</source> <year>2015</year>, <volume>10</volume> (<issue>8</issue>), <fpage>1770</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Nowak</surname>, <given-names>R. P.</given-names></string-name>; <string-name><surname>DeAngelo</surname>, <given-names>S. L.</given-names></string-name>; <string-name><surname>Buckley</surname>, <given-names>D.</given-names></string-name>; <string-name><surname>He</surname>, <given-names>Z.</given-names></string-name>; <string-name><surname>Donovan</surname>, <given-names>K. A.</given-names></string-name>; <string-name><surname>An</surname>, <given-names>J.</given-names></string-name>; <string-name><surname>Safaee</surname>, <given-names>N.</given-names></string-name>; <string-name><surname>Jedrychowski</surname>, <given-names>M. P.</given-names></string-name>; <string-name><surname>Ponthier</surname>, <given-names>C. M.</given-names></string-name>; <string-name><surname>Ishoey</surname>, <given-names>M.</given-names></string-name>; <string-name><surname>Zhang</surname>, <given-names>T.</given-names></string-name>; <string-name><surname>Mancias</surname>, <given-names>J. D.</given-names></string-name>; <string-name><surname>Gray</surname>, <given-names>N. S.</given-names></string-name>; <string-name><surname>Bradner</surname>, <given-names>J. E.</given-names></string-name>; <string-name><surname>Fischer</surname>, <given-names>E. S.</given-names></string-name>, <article-title>Plasticity in binding confers selectivity in ligand-induced protein degradation</article-title>. <source>Nat Chem Biol</source> <year>2018</year>, <volume>14</volume> (<issue>7</issue>), <fpage>706</fpage>&#x2013;<lpage>714</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Hughes</surname>, <given-names>S. J.</given-names></string-name>; <string-name><surname>Ciulli</surname>, <given-names>A.</given-names></string-name>, <article-title>Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical de-graders</article-title>. <source>Essays Biochem</source> <year>2017</year>, <volume>61</volume> (<issue>5</issue>), <fpage>505</fpage>&#x2013;<lpage>516</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Chan</surname>, <given-names>K. H.</given-names></string-name>; <string-name><surname>Zengerle</surname>, <given-names>M.</given-names></string-name>; <string-name><surname>Testa</surname>, <given-names>A.</given-names></string-name>; <string-name><surname>Ciulli</surname>, <given-names>A.</given-names></string-name>, <article-title>Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds</article-title>. <source>J Med Chem</source> <year>2018</year>, <volume>61</volume> (<issue>2</issue>), <fpage>504</fpage>&#x2013;<lpage>513</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Bondeson</surname>, <given-names>D. P.</given-names></string-name>; <string-name><surname>Smith</surname>, <given-names>B. E.</given-names></string-name>; <string-name><surname>Burslem</surname>, <given-names>G. M.</given-names></string-name>; <string-name><surname>Buhimschi</surname>, <given-names>A. D.</given-names></string-name>; <string-name><surname>Hines</surname>, <given-names>J.</given-names></string-name>; <string-name><surname>Jaime-Figueroa</surname>, <given-names>S.</given-names></string-name>; <string-name><surname>Wang</surname>, <given-names>J.</given-names></string-name>; <string-name><surname>Hamman</surname>, <given-names>B. D.</given-names></string-name>; <string-name><surname>Ishchenko</surname>, <given-names>A.</given-names></string-name>; <string-name><surname>Crews</surname>, <given-names>C. M.</given-names></string-name>, <article-title>Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead</article-title>. <source>Cell Chem Biol</source> <year>2018</year>, <volume>25</volume> (<issue>1</issue>), <fpage>78</fpage>&#x2013;<lpage>87 e5</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Testa</surname>, <given-names>A.</given-names></string-name>; <string-name><surname>Lucas</surname>, <given-names>X.</given-names></string-name>; <string-name><surname>Castro</surname>, <given-names>G. V.</given-names></string-name>; <string-name><surname>Chan</surname>, <given-names>K. H.</given-names></string-name>; <string-name><surname>Wright</surname>, <given-names>J. E.</given-names></string-name>; <string-name><surname>Runcie</surname>, <given-names>A. C.</given-names></string-name>; <string-name><surname>Gadd</surname>, <given-names>M. S.</given-names></string-name>; <string-name><surname>Harrison</surname>, <given-names>W. T. A.</given-names></string-name>; <string-name><surname>Ko</surname>, <given-names>E. J.</given-names></string-name>; <string-name><surname>Fletcher</surname>, <given-names>D.</given-names></string-name>; <string-name><surname>Ciulli</surname>, <given-names>A.</given-names></string-name>, <article-title>3-Fluoro-4-hydroxyprolines: Synthesis, Conformational Analysis, and Stereoselective Recognition by the VHL E3 Ubiquitin Ligase for Targeted Protein Degradation</article-title>. <source>J Am Chem Soc</source> <year>2018</year>, <volume>140</volume> (<issue>29</issue>), <fpage>9299</fpage>&#x2013;<lpage>9313</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Zorba</surname>, <given-names>A.</given-names></string-name>; <string-name><surname>Nguyen</surname>, <given-names>C.</given-names></string-name>; <string-name><surname>Xu</surname>, <given-names>Y.</given-names></string-name>; <string-name><surname>Starr</surname>, <given-names>J.</given-names></string-name>; <string-name><surname>Borzilleri</surname>, <given-names>K.</given-names></string-name>; <string-name><surname>Smith</surname>, <given-names>J.</given-names></string-name>; <string-name><surname>Zhu</surname>, <given-names>H.</given-names></string-name>; <string-name><surname>Farley</surname>, <given-names>K. A.</given-names></string-name>; <string-name><surname>Ding</surname>, <given-names>W.</given-names></string-name>; <string-name><surname>Schiemer</surname>, <given-names>J.</given-names></string-name>; <string-name><surname>Feng</surname>, <given-names>X.</given-names></string-name>; <string-name><surname>Chang</surname>, <given-names>J. S.</given-names></string-name>; <string-name><surname>Uccello</surname>, <given-names>D. P.</given-names></string-name>; <string-name><surname>Young</surname>, <given-names>J. A.</given-names></string-name>; <string-name><surname>Garcia-Irrizary</surname>, <given-names>C. N.</given-names></string-name>; <string-name><surname>Czabaniuk</surname>, <given-names>L.</given-names></string-name>; <string-name><surname>Schuff</surname>, <given-names>B.</given-names></string-name>; <string-name><surname>Oliver</surname>, <given-names>R.</given-names></string-name>; <string-name><surname>Montgomery</surname>, <given-names>J.</given-names></string-name>; <string-name><surname>Hayward</surname>, <given-names>M. M.</given-names></string-name>; <string-name><surname>Coe</surname>, <given-names>J.</given-names></string-name>; <string-name><surname>Chen</surname>, <given-names>J.</given-names></string-name>; <string-name><surname>bNiosi</surname>, <given-names>M.</given-names></string-name>; <string-name><surname>Luthra</surname>, <given-names>S.</given-names></string-name>; <string-name><surname>Shah</surname>, <given-names>J. C.</given-names></string-name>; <string-name><surname>El-Kattan</surname>, <given-names>A.</given-names></string-name>; <string-name><surname>Qiu</surname>, <given-names>X.</given-names></string-name>; <string-name><surname>West</surname>, <given-names>G. M.</given-names></string-name>; <string-name><surname>Noe</surname>, <given-names>M. C.</given-names></string-name>; <string-name><surname>Shanmugasundaram</surname>, <given-names>V.</given-names></string-name>; <string-name><surname>Gilbert</surname>, <given-names>A. M.</given-names></string-name>; <string-name><surname>Brown</surname>, <given-names>M. F.</given-names></string-name>; <string-name><surname>Cala-brese</surname>, <given-names>M. F.</given-names></string-name>, <article-title>Delineating the role of cooperativity in the design of potent PROTACs for BTK</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2018</year>, <volume>115</volume> (<issue>31</issue>), <fpage>E7285</fpage>&#x2013;<lpage>E7292</lpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Maniaci</surname>, <given-names>C.</given-names></string-name>; <string-name><surname>Hughes</surname>, <given-names>S. J.</given-names></string-name>; <string-name><surname>Testa</surname>, <given-names>A.</given-names></string-name>; <string-name><surname>Chen</surname>, <given-names>W.</given-names></string-name>; <string-name><surname>Lamont</surname>, <given-names>D. J.</given-names></string-name>; <string-name><surname>Rocha</surname>, <given-names>S.</given-names></string-name>; <string-name><surname>Alessi</surname>, <given-names>D. R.</given-names></string-name>; <string-name><surname>Romeo</surname>, <given-names>R.</given-names></string-name>; <string-name><surname>Ciulli</surname>, <given-names>A.</given-names></string-name>, <article-title>Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation</article-title>. <source>Nat Commun</source> <year>2017</year>, <volume>8</volume> (<issue>1</issue>), <fpage>830</fpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Banaszynski</surname>, <given-names>L. A.</given-names></string-name>; <string-name><surname>Liu</surname>, <given-names>C. W.</given-names></string-name>; <string-name><surname>Wandless</surname>, <given-names>T. J.</given-names></string-name>, <article-title>Characterization of the FKBP.rapamycin.FRB ternary complex</article-title>. <source>J Am Chem Soc</source> <year>2005</year>, <volume>127</volume> (<issue>13</issue>), <fpage>4715</fpage>&#x2013;<lpage>21</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Andersen</surname>, <given-names>P. S.</given-names></string-name>; <string-name><surname>Schuck</surname>, <given-names>P.</given-names></string-name>; <string-name><surname>Sundberg</surname>, <given-names>E. J.</given-names></string-name>; <string-name><surname>Geisler</surname>, <given-names>C.</given-names></string-name>; <string-name><surname>Karjalainen</surname>, <given-names>K.</given-names></string-name>; <string-name><surname>Mariuzza</surname>, <given-names>R. A.</given-names></string-name>, <article-title>Quantifying the energetics of cooperativity in a ternary protein complex</article-title>. <source>Biochemistry</source> <year>2002</year>, <volume>41</volume> (<issue>16</issue>), <fpage>5177</fpage>&#x2013;<lpage>84</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Palau</surname>, <given-names>W.</given-names></string-name>; <string-name><surname>Di Primo</surname>, <given-names>C.</given-names></string-name>, <article-title>Single-cycle kinetic analysis of ternary DNA complexes by surface plasmon resonance on a decaying surface</article-title>. <source>Biochimie</source> <year>2012</year>, <volume>94</volume> (<issue>9</issue>), <fpage>1891</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Domenici</surname>, <given-names>F.</given-names></string-name>; <string-name><surname>Frasconi</surname>, <given-names>M.</given-names></string-name>; <string-name><surname>Mazzei</surname>, <given-names>F.</given-names></string-name>; <string-name><surname>D&#x2019;Orazi</surname>, <given-names>G.</given-names></string-name>; <string-name><surname>Bizzarri</surname>, <given-names>A. R.</given-names></string-name>; <string-name><surname>Cannistraro</surname>, <given-names>S.</given-names></string-name>, <article-title>Azurin modulates the association of Mdm2 with p53: SPR evidence from interaction of the full-length proteins</article-title>. <source>J Mol Recognit</source> <year>2011</year>, <volume>24</volume> (<issue>4</issue>), <fpage>707</fpage>&#x2013;<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Fairhead</surname>, <given-names>M.</given-names></string-name>; <string-name><surname>Howarth</surname>, <given-names>M.</given-names></string-name>, <article-title>Site-specific biotinylation of purified proteins using BirA</article-title>. <source>Methods Mol Biol</source> <year>2015</year>, <volume>1266</volume>, <fpage>171</fpage>&#x2013;<lpage>84</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Beckett</surname>, <given-names>D.</given-names></string-name>; <string-name><surname>Kovaleva</surname>, <given-names>E.</given-names></string-name>; <string-name><surname>Schatz</surname>, <given-names>P. J.</given-names></string-name>, <article-title>A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation</article-title>. <source>Protein Sci</source> <year>1999</year>, <volume>8</volume> (<issue>4</issue>), <fpage>921</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Karlsson</surname>, <given-names>R.</given-names></string-name>; <string-name><surname>Katsamba</surname>, <given-names>P. S.</given-names></string-name>; <string-name><surname>Nordin</surname>, <given-names>H.</given-names></string-name>; <string-name><surname>Pol</surname>, <given-names>E.</given-names></string-name>; <string-name><surname>Myszka</surname>, <given-names>D. G.</given-names></string-name>, <article-title>Analyzing a kinetic titration series using affinity biosensors</article-title>. <source>Anal Bi-ochem</source> <year>2006</year>, <volume>349</volume> (<issue>1</issue>), <fpage>136</fpage>&#x2013;<lpage>47</lpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Copeland</surname>, <given-names>R. A.</given-names></string-name>, <article-title>The drug-target residence time model: a 10-year retrospective</article-title>. <source>Nat Rev Drug Discov</source> <year>2016</year>, <volume>15</volume> (<issue>2</issue>), <fpage>87</fpage>&#x2013;<lpage>95</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Riching</surname>, <given-names>K. M.</given-names></string-name>; <string-name><surname>Mahan</surname>, <given-names>S.</given-names></string-name>; <string-name><surname>Corona</surname>, <given-names>C. R.</given-names></string-name>; <string-name><surname>McDougall</surname>, <given-names>M.</given-names></string-name>; <string-name><surname>Vasta</surname>, <given-names>J. D.</given-names></string-name>; <string-name><surname>Robers</surname>, <given-names>M. B.</given-names></string-name>; <string-name><surname>Urh</surname>, <given-names>M.</given-names></string-name>; <string-name><surname>Daniels</surname>, <given-names>D. L.</given-names></string-name>, <article-title>Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action</article-title>. <source>ACS Chem Biol</source> <year>2018</year>, <volume>13</volume> (<issue>9</issue>), <fpage>2758</fpage>&#x2013;<lpage>2770</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Costales</surname>, <given-names>M. G.</given-names></string-name>; <string-name><surname>Matsumoto</surname>, <given-names>Y.</given-names></string-name>; <string-name><surname>Velagapudi</surname>, <given-names>S. P.</given-names></string-name>; <string-name><surname>Disney</surname>, <given-names>M. D.</given-names></string-name> <article-title>Small Molecule Targeted Recruitment of a Nuclease to RNA</article-title>. <source>J Am Chem Soc</source> <year>2018</year>, <volume>140</volume> (<issue>22</issue>), <fpage>6741</fpage>&#x2013;<lpage>6744</lpage>.</mixed-citation></ref></ref-list>
<sec id="s6">
<p><fig id="ufig1" position="float" fig-type="figure">
<caption><p>Entry for the Table of Contents</p></caption>
<graphic xlink:href="451948_ufig1.tif"/>
</fig></p>
</sec>
</back>
</article>
